Phio Pharmaceuticals (NASDAQ:PHIO) posted its quarterly earnings data on Monday. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08), Fidelity Earnings reports.
PHIO stock opened at $0.34 on Wednesday. The firm has a market capitalization of $9.06 million, a P/E ratio of -0.33 and a beta of 1.83. The business has a 50-day moving average of $0.39. Phio Pharmaceuticals has a fifty-two week low of $0.27 and a fifty-two week high of $2.19. The company has a quick ratio of 8.52, a current ratio of 8.52 and a debt-to-equity ratio of 0.04.
Separately, ValuEngine raised shares of Phio Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd.
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
Recommended Story: Bull Market
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.